Argenx
ARGX
#494
Rank
HK$393.59 B
Marketcap
HK$6,298
Share price
0.81%
Change (1 day)
39.11%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2026 (TTM): HK$11.73 Billion

According to Argenx 's latest financial reports the company's current earnings are HK$4.66 Billion. In 2025 the company made an earning of HK$10.00 Billion, an increase over its 2024 earnings that were of HK$0.66 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) HK$11.73 B17.22%
2025 HK$10.00 B1400.64%
2024 HK$0.66 B-127.97%
2023 -HK$2.39 Billion-58.25%
2022 -HK$5.72 Billion80.17%
2021 -HK$3.17 Billion
2019 -HK$1.56 Billion124.86%
2018 -HK$0.7 Billion131.81%
2017 -HK$0.3 Billion
2015 -HK$0.15 Billion
2013 -HK$87.25 Million